ID: ALA199666

Max Phase: Preclinical

Molecular Formula: C24H25ClO3

Molecular Weight: 396.91

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCC(CC(=O)O)C(=O)c1ccc(C#Cc2ccc(Cl)cc2)cc1

Standard InChI:  InChI=1S/C24H25ClO3/c1-2-3-4-5-6-21(17-23(26)27)24(28)20-13-9-18(10-14-20)7-8-19-11-15-22(25)16-12-19/h9-16,21H,2-6,17H2,1H3,(H,26,27)

Standard InChI Key:  UOBFNJXLVSPHNN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.91

Molecular Weight (Monoisotopic): 396.1492

AlogP: 5.98

#Rotatable Bonds: 9

Polar Surface Area: 54.37

Molecular Species: ACID

HBA: 2

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.13

CX Basic pKa:

CX LogP: 6.85

CX LogD: 3.77

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.32

Np Likeness Score: -0.14

References

1. Ma D, Jiang Y, Chen F, Gong LK, Ding K, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q..  (2006)  Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.,  49  (2): [PMID:16420030] [10.1021/jm051101g]

2. Ti H, Zhou Y, Liang X, Li R, Ding K, Zhao X..  (2019)  Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs).,  62  (13): [PMID:30682248] [10.1021/acs.jmedchem.8b01520]

Source

Source(1):

• Scientific Literature